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Epidemiological studies have shown that long-term treatment with statins decreases the risk of 
developing Alzheimer’s disease.  Statins have pleiotropic effects by lowering the concentration of 
isoprenoid intermediates.  Although several studies have shown that statins may reduce amyloid beta 
protein levels, there have been few reports on the interaction between statins and tau.  We report here 
that pitavastatin reduces total and phosphorylated tau levels in a cellular model of tauopathy, and in 
primary neuronal cultures.  The decrease caused by pitavastatin is reversed by the addition of 
mevalonate, or geranylgeranyl pyrophosphate.  The maturation of small G proteins, including RhoA 
was disrupted by pitavastatin, as was the activity of glycogen synthase kinase 3(GSK3a major 
tau kinase.  Toxin A, inhibitor of glycosylation of small G proteins, and Rho kinase (ROCK) 
inhibitor decreased phosphorylated tau levels.  ROCK inhibitor also inactivated GSK3  Although 
the mechanisms responsible for the reduction in tau protein by pitavastatin require further 
examination, this report sheds light on possible therapeutic approaches to tauopathy. 
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The accumulation of filamentous inclusions in the central nervous system (CNS) in the form of 
neurofibrillary tangles (NFTs) is a pathologic hallmark of a group of neurodegenerative disorders, 
including Alzheimer’s disease (AD), progressive supranuclear palsy, corticobasal degeneration, 
frontotemporal dementia with parkinsonism linked to chromosome 17, and Niemann-Pick disease 
type C (Lee et a1., 2001).  NFTs are composed of the microtubule-associated protein tau, which is 
extensively phosphorylated when incorporated into these inclusions.  
There is increasing evidence that disturbances in cholesterol homeostasis play an important role in 
the pathogenesis of AD (Haley and Dietschy, 2000; Di Paolo and Kim, 2011).  Accumulation of free 
cholesterol in NFT-bearing neurons has been found compared with adjacent NFT-free neurons (Distl 
et al., 2001, 2003).  Cholesterol also accumulates in senile plaques, another major histopathological 
hallmark of AD (Mori et al., 2001; Panchal et al., 2010). 
Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins), effective for the treatment 
of hypercholesterolemia, block the production of mevalonate (MVA) (Fig. 1).  Statins also exhibit 
pleiotropic effects by modulating the isoprenylation (farnesylation or geranylation) of various 
proteins. 
It has been reported that long-term treatment of hypercholesterolemia with statins significantly 
reduces the prevalence of AD (Jick et al., 2000; Wolozin et al., 2007; Haag et al., 2009).  Several 
studies have demonstrated that statin treatment decreases the production of amyloid  protein (A), 
which consists senile plaques (Ostrowski et al., 2007 Abrahamsonet al., 2009.   
Recently, a transgenic model of tauopathy showed reduction of NFTs by statins in both the early 
and late stages (Boimel et al., 2009).  It was concluded that anti-NFT effects of statins may be related 
to their anti-inflammatory properties, because microglia was decreased in such brain.  Kurata et al. 
also reported that statins reduced numbers of phosphorylated tau-positive neurites as well as senile 
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plaques in aged amyloid precursor protein (APP) transgenic mice (2011). 
Pitavastatin was chosen in this study, because it is a novel statin with a strong cholesterol-lowering 
effect, ten times that of simvastatin or pravastatin (Kurata et al., 2010).  Another reason is that 
pitavastatin, unlike other statins, does not affect the control of type 2 diabetes mellitus (Gumprecht et 
al., 2010) which is another risk factor for AD (Sims-Robinson et al., 2010).  To determine the effects 
and mechanisms of pitavastatin, on tau metabolism, we used transfectant M1C cells, which 
overexpress human 4R0N tau through a tetracycline off (TetOff)-inducible mechanism.  The M1C 
transfectant cell line was derived from human neuroblastoma BE(2)-M17D cells and previous studies 
have demonstrated that these cells accumulate sarkosyl-insoluble tau aggregates and oligomeric tau 




Glass-bottom tissue culture dishes were purchased from Mat Tek Corporation (Ashland, MA, USA), 
and Lab-Tek chambered cover glass was from Nunc (Rochester, NY, USA).  Other tissue cultureware 
was obtained from B.D. Biosciences (Franklin Lakes, NJ, USA).  Pitavastatin was kindly provided 
by Kowa Pharmaceutical Co., Ltd. (Tokyo, Japan).  MVA, geranylgeranyl pyrophosphate (GGPP), 
and Clostridium difficile toxin A (Toxin A) were obtained from Sigma (St. Louis, MO, USA).  Rho 
kinase (ROCK) inhibitor, H-1152, was from Calbiochem (La Jolla, CA, USA).  Other chemicals were 
obtained from Sigma, unless otherwise indicated. 
2.2. Antibodies 
The locations of epitopes recognized by the different anti-tau antibodies used in the present study 
are shown in Fig. 2A.  These antibodies are well characterized and have been used in a number of 
previous studies (Gamblin et al., 2003; Ko et al., 2004; Hamano et al., 2008; DeTure et al., 2002; 
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LoPresti et al., 1995; Porzig et al., 2007).  The monoclonal antibody Tau5 was obtained from 
Invitrogen (Carlsbad, CA, USA); TauC3 and anti-RhoA were obtained from Santa Cruz (Santa Cruz, 
CA, USA); glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Rac1 were obtained from 
Millipore (Billerica, MA, USA); and anti-Cdc42 and anti-flotillin-1 were obtained from BD (San Jose, 
CA, USA).  Monoclonal antibodies to phosphorylated tau protein, PHF-1 and CP13 were obtained 
from Dr. Peter Davies (Albert Einstein University, Bronx, NY, USA).  Tau46 was obtained from Dr. 
Virginia M.-Y. Lee (University of Pennsylvania, Philadelphia, PA, USA).  Polyclonal antibodies to 
cleaved caspase3, glycogen synthase kinase 3 (GSK3), and phospho-GSK(Ser9) (pGSK3) were 
obtained from Cell Signaling (Danvers, MA, USA), and those to Rac1, Rab5b, and Rab 6 were 
purchased from Santa Cruz.  Antibodies were used at the following dilutions: Tau5 (1:1,000), Tau46 
(1:2,000), PHF-1 (1:200), CP13 (1:200), TauC3 (1:2,000), anti-cleaved caspase3 (1:500), anti-GAPDH 
(1:2,000), anti-RhoA (1:200), anti-Rac1 (1:1,000), anti-Rab4 (1:200), anti-Cdc42 (1:250), 
anti-flotillin-1(1:1,000), anti-GSK3 (1:1,000), and anti-pGSK3 (1:500). 
2.3. Cell Culture 
M1C cells were seeded at 1.5-2 × 10
6
cells/plate in Dulbecco’s modified Eagle’s medium containing 
10% fetal bovine serum, G418 (400 g/mL; Life Technologies, Gaithersburg, MD, USA), and Tet (2 
g/mL).  Twenty-four hours after seeding, tau expression was elicited by replacing spent medium 
with fresh medium containing 1 ng/mL Tet (TetOff induction).  Replica cultures of M1C cells were 
exposed to pitavastatin on day 4 of the TetOff induction, and harvested at the end of a day 5 (Fig. 2B).  
In the experiments on the time course of effects of pitavastatin, M1C cells were exposed to 1 M of 
pitavastatin from 0.5, 1, 1.5, 2, or 4 days before harvest at the end of day 5.  Other cultures were 
treated with MVA (250 M, Sigma) or GGPP (10 M) for 2 h before being exposed to pitavastatin.  
It has been shown that 250 M of MVA effectively reverses the inhibition of mevalonate pathway by 
statins (Ostrowski et al., 2007), and 10 M of GGPP effectively reverses the inhibition of 
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geranylgeranylation by statins (Masamura et al., 2003; Fuchs et al., 2008).   
2.4. Primary neuronal cultures 
Primary cortical neurons were isolated and purified from female and male mice (Slc:ICR) on 
embryonic day 16 (E16).  Isolated primary neurons were plated onto Lab-Tek chambered coverglass 
precoated with polyethyleneimine (Sigma) at a density of 5 × 10
4
 per well, or 3.5 cm plastic dish 
precoated with polyethyleneimine at a density of 4 × 10
5 
per dish for Western blot analysis.  The 
cultures were maintained in serum free Neurobasal medium (Invitrogen) and were treated with 5 M 
cytosine arabinoside (Ara-C) to inhibit proliferation of non neuronal cells (Han et al., 2005).  All 
experiments presented in this work were performed on pure neuronal cells (>95% neuronal purity 
assessed by immunostaining cultures using neuron specific Anti-NeuN (Milliopore)) on 14th day from 
start plating the cells. 
2.5. Fractionation of cell lysates 
M1C cells were harvested and homogenized in Tris buffer containing protease and phosphatase 
inhibitors (30 mM -glycerophosphate, 30 mM sodium fluoride, and protease inhibitor cocktail 
(Roche, Germany)), 1 mM EDTA, and 1 mM EGTA.  Homogenates were centrifuged at 180g for 15 
min to obtain cell lysates.  Portions of lysates were further fractionated based on solubility in Tris 
buffer or 2% sarkosyl to generate SN1, SN2, and S/P fractions, as reported previously (Hamano et al., 
2008; Sahara et al., 2002).  The SN1 fraction is the supernatant derived from centrifugation of lysates 
at 150,000g for 15 min at 4 °C.  The pellet was re-suspended in buffer containing 0.8 M NaCl, 10% 
sucrose, 10 mM Tris/HCl (pH 7.4), 1 mM EGTA, protease inhibitor cocktail, and 1% sarkosyl and 
centrifuged at 150,000g for 15 min to yield a supernatant (SN2) and sarkosyl-insoluble pellet (S/P).  
All supernatants and the sarkosyl-insoluble pellet re-suspended in Tris buffer were used immediately 
for immunoblotting, or were stored at -70 °C or -20 °C. 
2.6. Western blotting  
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Cell lysates or fractionated preparations were mixed with Laemmli sample buffer containing 1% 
-mercaptoethanol (ME).  Protein concentrations of cell lysates were determined by bicinchoninic 
acid assay (Thermo Scientific, Rockford, IL, USA).  Samples containing the same amounts of protein 
(10 g, corresponding to 0.1-0.2 × 105 cells per lane) were resolved by 10% SDS-polyacrylamide gel 
electrophoresis and were subsequently transferred onto polyvinylidene difluoride (PVDF) membranes 
(Immobilon P; Millipore) for immunoblotting.  Blots were immersed in 1% gelatin in Tris-buffered 
saline containing 0.1% Tween 20 (TBS-T) for 1 h at room temperature (RT).  After rinsing with 
TBS-T, blots were incubated with monoclonal antibodies Tau5, PHF-1, CP13, TauC3, anti-flotilin, 
anti-RhoA, anti-Cdc42, or anti-GAPDH, or polyclonal antibodies to Rab5b, Rab6, Rac1, GSK3, 
pGSK3 or cleaved caspase3, for 1 h at RT at the dilutions indicated above.  After the third rinse, 
blots were incubated with horseradish peroxidase-conjugated sheep anti-mouse IgG or goat anti-rabbit 
IgG for 30 min at RT.  After a final wash, immunoreactive proteins were visualized with an enhanced 
chemiluminescence (ECL) system (Amersham, Buckinghamshire, UK) (Hamano et al., 1997).  The 
intensity of immunoreactivity was quantified by capturing images using Photoshop CS version 8.01 
(Adobe, San Jose, CA, USA), and analyzed using Image J software
 
(NIH, Bethesda, MA, USA). 
2.7. mRNA expression 
To examine tau mRNA expression, total RNA was extracted from cells using TRIzol reagent 
(Invitrogen) and converted to cDNA for PCR amplification.  The PCR cycling conditions were: 
94 °C, 5 min (1 cycle): 94 °C, 30 s: 50 °C, 30 s: 72 °C, 20 s (29 cycles): 72 °C, 15 min.  Primer 
sequences for tau were 5’-TGAGCCCCGCCAGGAGTTC-3’ and 
5’-TTGGAGCGGGCGGGGTTTTTG-3’, and yielded products of 446 or 355 bp for tau isoforrms 
containing or lacking exon 2 (4R0N), respectively (Gendron et al., 2008).  Primer sequences for 
GAPDH were 5’-TTGATTTTCGAGGGATCTCG-3’ and 5’-GAGTCAACGGATTTGGTCGT-3’ 
(product size: 238 bp).  Quantitative real time PCR (QPCR) was carried out using 20 ng of cDNA per 
 8 
sample in a 20 μl reaction volume, with the StepOnePlus Realtime PCR System.  Relative gene 
expression was calculated using the CT methods (Bunpo et al., 2009).  All samples were run in 
triplicate.  To analyze Tau mRNA levels, the following TaqMan gene expression assays (Applied 
Biosystems) were used: MAPT (Hs00902188_ml) and GAPDH (Hs99999905_m1).    
2.8. Morphological study 
Cells were cultured on 24-well plates, and morphological studies before and after pitavastatin 
treatment were performed using an inverted microscope (IX-70; Olympus, Tokyo, Japan).  Images 
were captured by a digital camera (DP-70; Olympus).  Dead cell counts were estimated by ATP  
assay using The CellTiter-Glo Luminescent Cell Biability Assay Kit, according to the manufacturer’s 
instructions.   
2.9. Immunocytochemical study 
Cells grown on glass-bottom culture dishes were subjected to TetOff induction in the absence or 
presence of pitavastatin (2 M) for the final 24 h of induction.  After treatment, cells were washed 
with phosphate-buffered saline (PBS), permeabilized with 0.0001% saponin/PBS, and exposed to 
methanol at -20 °C prior to fixation in 2% paraformaldehyde/PBS.  Fixed samples were rinsed with 
100 mM Tris-saline (TS), blocked with TS containing 3% goat serum, and then incubated with P44 
antibody (1:100) followed by Alexa 594 anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) and 
Alexa 488 anti-mouse IgG (Molecular Probes).  A confocal fluorescence microscope (TCS SP II; 
Leica, Heidelberg, Germany) was used to visualize immunoreactivity. 
2.10. Membrane localization and Western blotting for GTPases  
M1C cells were treated with pitavastatin for 24 h.  Cellular fractionation was carried out as 
described by Zhao et al. (2002).  Briefly, following pitavastatin treatment, cells were lysed by 
incubation in relaxation buffer (100 mM KCl, 3 mM NaCl, 3.5 mM MgCl2, 1.25 mM EGTA and 10 
mM PIPES, pH 7.3) on ice for 15 min followed by 10 s sonication.  Cells were removed by 
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centrifugation at 500g for 5 min at 4 °C.  The resulting supernatant was removed (cytosolic fraction), 
and the membrane pellets were resuspended in relaxation buffer (membrane fraction). 
2.11. Immunoblotting of the inactive form of GSK3
GSK3 was analyzed by comparing the phosphorylation levels of GSK3 (Ser9) before and after 
pitavastatin treatment, according to the method described by Ma et al. (2009). 
2.12. Toxin A and Rho kinase (ROCK) inhibitor assay  
The effects of Toxin A were analyzed by treating cells with 500 ng/mL of Toxin A or 1 M of 
ROCK inhibitor for the final 15 h of the 5-day TetOff induction period.  The total amount of tau 
protein was determined by Western blotting before and after Toxin A or ROCK inhibitor treatment.   
2.13. Statistical analysis  
All values in the figures are expressed as the mean ± SEM.  Differences between groups were 
analyzed by Student’s t-test (SPSS version 17.0), with findings of p<0.05 considered significant. 
IC50 values were calculated by non linear regression. 
 
3. Results 
3.1. Pitavastatin dose-dependently decreases tau levels and inhibits tau phosphorylation 
To examine the effect of pitavastatin on tau, M1C cells were induced to express tau for 5 days and 
exposed to pitavastatin (0.5, 1, 2, 5, or 10 M) during the final day of the induction period.  Control 
cultures were treated with DMSO, the vehicle used to dilute pitavastatin.  Lysates derived from 
cultures were analyzed by Western blot using antibody Tau5 or Tau46.  These samples were also 
probed with anti-GAPDH antibody to verify that loading among lanes was equal (Fig. 3).  Total tau 
levels were decreased in a dose-dependent fashion following pitavastatin treatment, except for that at 
the highest dose examined (10 M).  At this dose, a ~50 kDa tau species became evident.  In 
cultures treated with 1 M pitavastatin, antibody Tau5 detected 45- to 62-kDa bands at 68 ± 17.3% of 
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the level displayed in the vehicle control (mean ± SEM) and antibody Tau46 detected 50- to 58-kDa 
bands at 62.3 ± 10.6% of the level displayed in the vehicle control.   
To determine whether this decrease in tau was the result of changes in tau mRNA levels, mRNA 
expression was examined.  As shown in Fig. 5, pitavastatin had no effect on tau mRNA levels, as 
determined by semiquantitative RT-PCR (A), as well as QPCR (B). 
Next, phosphorylated tau in lysates was assessed using phospho-tau antibodies that recognize 4 
epitopes collectively (Fig. 2A), and blots were subsequently reprobed using GAPDH and Tau5, Tau46, 
or P44 antibodies.  In cultures treated with 1 M pitavastatin, antibodies PHF-1 and CP13 detected 
52- to 68-kDa bands at 58 ± 5.4% and 40.1 ± 7.2%, respectively, of the level displayed in the vehicle 
control (Fig. 3). 
In the time course experiments, 1.5 days (36 h) of 1 M pitavastatin treatment most effectively 
decreased total tau levels, as well as phosphorylated tau levels (Fig. 4).   
Of note, pitavastatin treatment decreased the ratio of phosphorylated tau to total tau (PHF-1/Tau5 
or CP13/Tau5) (Fig. 6A).  However, the level of Ser9-phosphorylated GSK3increased following 
pitavastatin treatment (Fig. 6B), indicating that GSK3 was inactivated by pitavastatin.  Given that 
GSK3 is known to phsophorylate tau, these findings suggest that pitavastatin may decrease levels of 
phosphorylated tau, at least in part, by inhibiting GSK3  
3.2. Pitavastatin decreases the accumulation of sarkosyl-insoluble tau in M1C cells 
To assess whether pitavastatin causes the clearance of soluble versus insoluble tau, M1C cells were 
induced to express tau for 5 days and exposed to 0.5 M or 2 M of pitavastatin on day 4.  Cell 
lysates were then fractionated to derive SN1 (buffer soluble), SN2 (salt- and sarkosyl-soluble), and S/P 
(sarkosyl-insoluble pellet) fractions.  A portion of each sample was analyzed by Western blot using 
antibody Tau5 (Fig. 7).  Total tau levels, including those in the sarkosyl-insoluble fraction, were 
decreased by 2 M, as well as 0.5 M pitavastatin. 
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3.3 Pitavastatin decreases endogenous tau, as well as phosphorylated tau, in primary neurons 
To test the effect of pitavastatin on endogenous tau, primary neuronal cultures were treated with 
pitavastatin (0.2, 1 and 5 M).  This led to a reduction in total tau levels, and in levels of 
phosphorylated tau in a dose-dependent manner, as assessed by Western blotting.  ATP levels did not 
change after treatment with 0.5, 1, or 5 M of the statin.  The IC50 value of pitavastatin obtained from 
the ATP assay was 120 M for neuronal cells (Fig. 8A).  A reduction of phosphorylated tau (CP13) 
following pitavastatin treatment was also observed by immunocytochemical analysis (Fig. 8B). 
3.4. Treating cells with low-to-moderate concentrations of pitavastatin does not cause cell death   
To examine the effect of pitavastatin on cell morphology, M1C cells were cultured on 24-well 
plates, and examined by phase-contrast microscopy (Fig. 9A).  There were no obvious differences 
between cultures treated with vehicle and pitavastatin at concentrations ranging from 0.5-5 M.  
However, high-dose pitavastatin (10 M) induced alterations of cell body morphology suggestive of 
apoptosis.   
Next, we evaluated whether pitavastatin induced cell death.  Low-to-moderate dose pitavastatin 
(0.1-5 M) did not further reduce the number of living cells, but high-dose pitavastatin (10 M) 
reduced the number by about 30% (Fig. 9B).  IC50 value obtained from the ATP assay was 140 M 
pitavastatin for M1C cells.  Congruent with these findings, cleaved caspase 3 was not detected 
following treatment with low-dose pitavastatin (0.5-2 M).  A weak band of cleaved caspase 3 was 
detected after treatment with 5 M pitavastatin, while high concentrations of pitavastatin (10 M) 
caused caspase activation (Fig. 9C).  Interestingly, this activation correlated with the emergence of 
caspase-cleaved tau, as detected by TauC3 (Fig. 9D). 
3.5. Reduction of tau by pitavastatin treatment is reversed by the addition of mevalonate   
By inhibiting HMG-CoA reductase, statins also diminish the production of MVA and isoprenoids 
(Fig. 1).  To determine whether exogenous MVA could prevent reduction in tau observed in cells 
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treated by pitavastatin, M1C cells induced to express tau were co-treated with 2 M pitavastatin and 
MVA (250 M).  As shown in Fig. 10A and 10B, MVA reversed the decrease in tau normally caused 
by pitavastatin treatment, suggesting that this decrease was not a toxic effect of pitavastatin, but 
instead occurred as a result of the decreased production of isoprenoids.  This is further supported by 
the fact that GGPP also reversed pitavastatin-induced tau clearance, showing that this effect was 
dependent on the inhibition of protein geranylgeranylation (Fig. 10C). 
3.6. Pitavastatin treatment decreased membrane-associated small G proteins 
Geranylgeranylation of small G proteins of the Rho family is an essential prerequisite for their 
anchoring in the cell membrane and thus for their activity.  Given that pitavastatin decreased tau 
levels and given that this effect was blocked by GGPP, we examined whether pitavastatin influenced 
the cellular localization of small G proteins.  Pitavastatin treatment decreased levels of 
membrane-associated small G proteins, including RhoA, Rac1, Cdc42, Rab1B, Rab4, Rab5, and Rab6, 
while increasing levels of these proteins in the cytosolic fraction.  MVA reversed the decrease in 
membrane-associated small G proteins (Fig. 11). 
3.7. Toxin A and Rho kinase (ROCK) inhibitor treatment decreased tau levels 
Toxin A is a robust and specific Rho family inhibitor often used to delineate the Rho 
family-dependent effects of statins (Voth and Ballard, 2005).  Toxin A treatment (500 ng/mL) 
decreased total tau levels (Fig. 11A).  ROCK inhibitor (1 M) also decreased total and 
phosphorylated tau (Fig. 12B).  Of interest, treatment of cells with ROCK inhibitor led to the 
inactivation of GSK3by increasing GSK3phosphorylation at Ser9 (Fig. 11C).  These findings 
were replicated using a second ROCK inhibitor (Y-27632, Wako, Osaka, Japan) (data not shown).  





Recently, interest in the therapeutic potential of statins for the treatment of AD has developed.  
Indeed, some evidence of their beneficial effects in mild to moderate AD has been reported (Jick et al., 
2000; Wolozin et al., 2000; Rockwood et al., 2002; Hajjar et al., 2002; Zamrini et al., 2004; Dufouil et 
al., 2005).  Furthermore, epidemiological studies have shown that hypercholesterolemia is a risk 
factor for AD (Haley and Dietschy, 2000; Di Paolo and Kim, 2011).  A randomized controlled trial of 
atorvastatin in mild to moderate AD, however, was not associated with significant clinical benefit 
(Feldman et al., 2010). 
We have shown herein that pitavastatin treatment markedly reduces tau levels, as well as tau 
phosphorylation, in both a cellular model of tauopathy and in primary neurons.  This is in agreement 
with a study conducted by Boimel et al. (2009), who reported that statins reduce NFTs in a model of 
tauopathy.  They showed that treatment (1 month) with simvastatin or atorvastatin reduced both NFT 
burden and lectin-positive microglia.  Simvastatin also improved memory deficits, as evaluated by 
T-maze performance, in young mice treated for 8 months.  Kurata et al. also reported that statin 
(atorvastatin and pitavastatin) reduced the numbers of senile plaques and tau positive neuritis in APP 
transgenic mice (2011). 
Of particular interest, recent clinical observations have shown that simvastatin, a CNS-permeable 
statin, decreases the amount of phosphorylated tau in the cerebrospinal fluid of AD patients (Riekse et 
al., 2006).  Kurzepa et al. (2008) also reported that administration of simvastatin following stroke 
prevents increase in the serum levels of tau protein.   
Nonetheless, it must be indicated that, despite the cholesterol lowering effects of statins, the role of 
cholesterol in tau metabolism remains controversial.  Fan et al. (2001) reported that cholesterol 
deficiency induced by compactin in cultured neurons results in hyperphosphorylation of tau 
accompanied by axonal degeneration associated with microtubule depolymerization.  Meske et al. 
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(2003) also reported that lovastatin treatment transiently increases tau phosphorylation, causing 
alterations in the microtubule system in a rat primary neuron culture model. 
In our study, we found the effects of pitavastatin on tau to be dose-dependent.  Low-to-moderate 
doses of pitavastatin, which did not activate caspase, reduced total and phosphorylated tau levels.  In 
contrast, high dose pitavastatin activated caspase 3 and increased levels of caspase-cleaved tau, which 
may facilitate tau aggregation.  We also found that a higher dose of pitavastatin treatment caused 
morphological changes suggestive of apoptosis (Fig. 9A).  These findings are similar to the results of 
a study by Meske et al. (2003).  However, Bar-On et al. (2008) reported that 10 M statin (lovastatin, 
simvastatin, or pravastatin) treatment for 24 h did not cause cell death in B103 neuroblastoma cells.  
These inconsistencies in findings may be due to the different types of cells, statins and concentration 
used among studies. 
Statins exhibit pleiotropic effects through their ability to lower the concentration of isoprenoid 
intermediates, such as GGPP or FPP.  Members of the Rho and Rab family of small G proteins 
require the addition of these isoprenyl moieties at their C-terminus for acquisition of normal GTPase 
function.  The Rho subfamily of small G proteins, which include RhoA, Rac, and Cdc42, was first 
recognized for their regulatory effects on cytoskeletal rearrangement (Nobes and Hall, 1995).  The 
findings of the present study suggest that inhibition of small G protein maturation may participate in 
the reduction of tau levels, since the addition of MVA or GGPP blocked pitavastatin-induced tau 
clearance.  In support of this, pitavastatin treatment led to altered membrane distribution of small G 
proteins, including RhoA, Rac1, Rab5, and Rab6 proteins (Fig. 11).  Interestingly, Eckert et al. 
(2009) recently reported that FPP and GGPP levels in brains of AD patients are upregulated compared 
with that in those of healthy individuals, and that, following simvastatin treatment, these levels are 
downregulated.  Scheper et al. (2007) also reported that Rab6 is upregulated in AD brain and that it 
colocalizes with hyperphosphorylated tau.   
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It has been reported that Galpha13 activation by lysophotidic acid (LPA) results in RhoA activation.  
This RhoA activation activates GSK3 (Sayas et al., 2002).  We speculated that the decrease in 
phosphorylated tau by pitavastatin treatment was caused by GSK3 inactivation through RhoA 
inactivation.  GSK3 inactivation was observed following low-dose pitavastatin treatment (Fig. 5B), 
consistent with the findings of Ma et al. (2009).  Rho-GTPase activates the Rho kinases, ROCK1/2.  
Rho-GTPase, ROCK1/2, and PAK1-3 are important regulators of synaptic plasticity especially in 
maintaining the actin cytoskeleton of dendritic spines.  Recently, it was suggested that RhoA/ROCK 
acts through myosinII to destabilize microtubules (Takesono et al., 2010).   
We found that ROCK inhibitor led to GSK3inhibition by increasing its phosphorylation, and also 
decreased the levels phosphorylated tau (Fig. 12B, C).  Further evaluation is needed on the 
interaction between tau and Rho/ROCK, and the induction of NFT formation by microtubule 
disturbances and Rho/ROCK signaling. 
Overall, our findings provide a insight into how statins may reduce total and phosphorylated tau 
levels in AD patients and highlight the implications of Rho/ROCK for the metabolism including 
phosphorylation of tau.  Although the mechanisms responsible for the reduction in tau protein by 
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Figure legends 
Fig. 1. Mevalonate cascade and its inhibitors.  Statins inhibit HMG-CoA reductase and block the 
synthesis of isoprenoids (FPP/GGPP) and cholesterol.  Post-translational geranylgeranylation and 
farnesylation of small G proteins of the Rho/Rab family are required for these proteins to become 
anchored to the cell membrane, and thus become active.  FPP, farnesyl pyrophosphate; GGPP, 
geranylgeranyl pyrophosphate. 
Fig. 2. (A) Schematic representation of 4R0N tau and distinct epitopes recognized by different tau 
antibodies.  (B) Treatment schedule of tetracycline off (TetOff) induction.  On day 0, TetOff 
induction with initiated by decreasing the concentration of tetracycline in the medium from 2,000 
ng/mL to 1 ng/mL.  On day 4, pitavastatin treatment was initiated.  On day 5, cells were harvested. 
Fig. 3.  Dose-dependent effects of pitavastatin treatment on tau. 
M1C cells were subjected to a 5-day TetOff induction of tau expression and cells were exposed to 
pitavastatin (statin) at 0.5, 1, 2, 5, or 10 M during the final day of induction, 1 day before the end of 
induction.  Cultures treated with DMSO served as vehicle controls (0 M).  Lysates derived from 
cultures were immunoblotted with antibodies Tau5 (A), Tau46 (B), PHF-1 (C), and CP13 (D).  
GAPDH was used as an internal standard.  (A) The amount of Tau-5-immunopositive tau decreased 
in a dose-dependent fashion when cells were treated with pitavastatin at low to moderate 
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concentrations (0.5-5 M).  However, at the highest doses tested (10 M), a slight increase in the 
amount of tau was noted compared to tau levels in cultures treated with 5 M of pitavastatin.  (B) 
Bands immunopositive for Tau46, which recognizes the C-terminus of tau, were also decreased.  
When the cells were treated in response to 10 M statin, the amount of tau did not increase, suggesting 
that the Tau5-immunoreactive tau species that increased with 10 M pitavastatin treatment was a 
C-terminus-truncated product of tau.  (C) Phosphorylated tau detected by PHF-1 and by CP13 (D) 
were also decreased.  However, 10 M statin treatment slightly increased the amount of 
phosphorylated tau detected by PHF-1.  Bar: ± SEM, *p<0.05, **p<0.01. N=5. 
Fig.4.  Time course of the effects of pitavastatin on tau levels. 
Time course experiments showed that 1.5 days (36 h) of pitavastatin treatment most effectively 
reduced total and phosphorylated tau protein levels.  Bar: ± SEM, *p<0.05, **p<0.01. N=5. 
Fig. 5.  Pitavastatin treatment does not alter tau mRNA levels. 
Tau mRNA levels were examined after pitavastatin (statin) treatment by reverse transcriptase PCR (A),  
and quantitative real-time PCR (B).  The statin was found to have no effect on tau mRNA expression.   
Bar: ± SEM, **p<0.01, NS: not significant. N=6. NI: non-induced cells. 
Fig. 6.  Pitavastatin decreases tau phosphorylation by inhibiting GSK3.   
(A) The ratio of phosphorylated to total tau was decreased following pitavastatin (statin) treatment 
(PFH-1/Tau5 or CP13/Tau5).  (B) Satin treatment increased GSK3 phosphorylation at Ser9, which 
renders GSK3 inactive.  Bar:  SEM, *p<0.05. N= 5. 
Fig. 7.  Pitavastatin suppresses accumulation of sarkosyl-insoluble tau in M1C cells.   
Lysates from M1C cells induced to express tau for 5 days were exposed to 0.5 M or 2 M 
pitavastatin (statin) (A) on day 4, and then fractionated into SN1 (buffer soluble), SN2 (salt- and 
sarkosyl-soluble), and S/P (sarkosyl-insoluble pellet) fractions.  Each fraction was analyzed by 
Western blotting using Tau5 antibody.  Compared to that in vehicle-treated cells, the amount of tau 
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was decreased in all fractions obtained from cells treated with 2 M as well as 0.5 M pitavastatin.   
Fig. 8.  A. Pitavastatin lowers endogenous tau levels in primary neuronal cultures.   
To examine the effect on endogenous tau, primary neurons were treated with pitavastatin (0.2, 1, or 5 
M) for 24 h.  (A) Pitavastatin caused a reduction in total tau, as well as phosphorylated tau (PHF-1, 
and CP13) levels, as assessed by Western blotting.  The IC50 value obtained from the ATP assay was 
120 M for primary neurons.  (B) Immunocytochemical analysis also showed a reduction of 
phosphorylated tau protein (CP13) by 0.5 M of statin.  Bar: 10 m. 





Fig. 9.  High-dose pitavastatin causes morphological changes and cell death.   
(A) High-dose pitavastatin (statin) (10 M) treatment induced morphological changes including 
shrinking of the cell body and dendritic processes.  However, low to moderate doses of pitavastatin 
(<5 M) did not result in marked morphological changes compared to untreated cells.  (B) ATP 
assays demonstrated that the treatment of tau-expressing cells with low to moderate doses (0.1-5 M) 
of pitavastatin did not affect viability.  In contrast, treatment with 10 M of pitavastatin decreased the 
number of live cells.  (C) High-dose statin activates caspase 3 and induces caspase cleavage of tau.  
Cleaved caspase 3, indicative of active caspase 3, was not detected in cells treated with 0-2M statin; 
however, weak bands were detected after 5M treatment, and stronger bands were detected after 
10M treatment.  The IC50 value of pitavastatin obtained from ATP assays was 140 M for M1C 
cells.  (D) Cells treated with 10M statin were immunopositive for TauC3, which detects 
caspase-cleaved tau.  NI: non-induced cells. 
Fig. 10.  Mevalonate (MVA) and geranylgeranyl pyrophosphate (GGPP) reversed 
pitavastatin-induced decreases in tau levels.   
(A) The decrease in tau caused by pitavastatin (statin) treatment was reversed by co-treatment with 
250 M MVA.  (B) Immunocytochemical analysis of cells demonstrated that non-induced cells 
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exhibited no tau accumulation (NI), while TetOff-induced cells (DMSO) exhibited tau expression.  
After treatment of cells with 2 M statin, tau accumulation was reduced.  However, in cells 
co-treated with statin and MVA (statin + MVA), the immunoreactivity for tau was recovered.  (C) 
The reduction of tau by statin treatment was also reversed by co-treating cells with 10 M GGPP.  
Statin: 2 M pitavastatin, MVA: 250 M MVA, GGPP: 10 M GGPP. 
Fig. 11.  Pitavastatin inhibits small G protein membrane association. 
After 2 M pitavastatin (statin) treatment, the distribution of small G proteins (RhoA, Rac1, Cdc42, 
Rab1B, Rab4, Rab5 and Rab6) shifted from the membrane fraction to the cytosolic fraction.  This 
was not observed when cells were co-treated with both statin and mevalonate (MVA).  Flotilin was 
used as a marker for the membrane fraction, whereas GAPDH was a marker for the cytoplasmic 
fraction. 
Fig. 12.  Clostridium difficile Toxin A (Toxin A) and a Rho kinase (ROCK) inhibitor decreased tau. 
(A) The relationship between reduction in tau and the inactivation of geranylated Rho family proteins 
(RhoA, Rac, and Cdc42) was examined by treating cells with 500 ng/mL of Toxin A.  Toxin A 
treatment reduced total tau protein levels.  The IC50 value of Toxin A obtained from ATP assays was 
1,630 ng/mL.  -: DMSO control, +: Toxin A, cells treated with 500 ng/mL Toxin A.  (B) The ROCK 
inhibitor (1 M) decreased total (Tau5) and phosphorylated (PHF-1 and CP13) tau levels.  The IC50 
value of ROCK inhibitor obtained from ATP assays was 84 M.  (C) The ROCK inhibitor (1 M) 
inactivated GSK3by increasing its phosphorylation at Ser9.  -: DMSO control, +: cells treated with 
1 M ROCK inhibitor.   
